Rationalisation of Polypharmacy in the Elderly by the RASP Instrument
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 200
Summary
- Conditions
- Healthy
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: Single (Care Provider)Primary Purpose: Health Services Research
Participation Requirements
- Age
- Between 65 years and 125 years
- Gender
- Both males and females
Description
Older persons take on average multiple drugs. As people age, there is an apparent increase in pharmacodynamic sensitivity to different making the patient more prone to experience side effects. Alterations in body composition and concomitant changes in pharmacokinetic parameters can also result in a ...
Older persons take on average multiple drugs. As people age, there is an apparent increase in pharmacodynamic sensitivity to different making the patient more prone to experience side effects. Alterations in body composition and concomitant changes in pharmacokinetic parameters can also result in a higher risk for adverse drug events. All these factors make the older person, notwithstanding the heterogeneity of this population, more vulnerable for the negative consequences of polypharmacy. Polypharmacy is a cause of negative clinical outcomes but it still remains unclear which intervention or set of interventions should be used to optimize the prescription of pharmacotherapy in the elderly patient. Therefore, the investigators developed the RASP (RASP = Rationalisation of home medication by an adjusted STOPP-list in older patients; STOPP = Screening Tool of Older Persons' potentially inappropriate Prescriptions), a list as tool to reduce polypharmacy adapted to Belgian national prescribing tendencies within geriatric wards. Content and reliability of the RASP have been validated and the investigators aim to further study the impact of the systematic implementation of this RASP on geriatric wards in a prospective cluster randomized controlled trial.
Tracking Information
- NCT #
- NCT01513265
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Lorenz Van der Linden, PharmD Universitaire Ziekenhuizen Leuven